REGENXBIO Inc. (RGNX)
The price, the headline numbers and the latest news, in one place.
REGENXBIO Inc. (RGNX) Stock Price, Analysis & Data
| Bid | 8.1 |
| Market Cap | 563M |
| Revenue (ttm) | 174M |
| Net Income (ttm) | -196M |
| 0.93 | |
| -3.78 | |
| n/a | |
| -2.84 | |
| P/B (ttm) | 6.44 |
| P/S (ttm) | 3.23 |
| Earnings Date | Nov 5, 2026 |
| Ask | 10.76 |
| Volume | 1,029,046 |
| Avg. Volume (20D) | 1,959,074 |
| Open | 8.69 |
| Previous Close | 8.56 |
| Day's Range | 8.39 - 8.82 |
| 52-Week Range | 5.46 - 16.19 |
| Analyst | n/a |
| Price Target | 19 (122.74%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chron...
Financial Performance
In 2025, REGENXBIO's revenue was 170.44M, an increase of 104.54% compared to the previous year's 83.33M. Earnings were -193.88M, a decrease of -14.63%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for RGNX stock is "null". The 12-month stock price forecast is 19, which is upside of 122.74% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $108.02M misses estimates by $0, with 405.73% YoY growth.
- EPS of 0.43 exceeds estimates by 0.54, with 131.16% YoY growth.
Analysts project revenue of ... Upgrade
